Ultrasep ES Pharm-RP8e is a silica-based HPLC column with an endcapped C8 bonded phase, optimized for pharmaceutical applications requiring balanced hydrophobicity and reduced silanol activity. The endcapping process minimizes secondary interactions, leading to sharper peak shapes and improved reproducibility, particularly for basic and polar analytes.
Compared to conventional C18 phases, the shorter C8 chains provide faster elution while maintaining reliable selectivity. This makes Pharm-RP8e a highly versatile option for pharmaceutical quality control, impurity profiling, and stability-indicating assays.
Ultrasep ES Pharm-RP8e combines balanced hydrophobicity with reduced silanol activity – the reliable choice for pharmaceutical HPLC separations where reproducibility and peak symmetry are critical.
Silica-based stationary phase with endcapped C8 bonded chemistry
Reduced silanol activity for improved peak symmetry
Balanced hydrophobic retention for faster separations
High reproducibility and robust lifetime under routine use
Available particle size: 5 µm
Pharmaceutical impurity profiling and stability testing
Analysis of basic and polar drugs with improved peak shapes
Quality control in pharmaceutical production
Method development requiring reduced secondary interactions
| Particle Size |
|
|---|---|
| Pore Size | 100 Å |
| Particle Type | |
| Separation Mode | |
| USP Code | |
| Endcapping | Yes |
| pH Range | 2 - 8 |
| Phase | Material Number |
|---|---|
| Ultrasep ES Pharm-RP8e, 5 µm | u15.p8e. |